Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the e2 envelope glycoprotein

Rodion Gorchakov, Eryu Wang, Grace Leal, Naomi L. Forrester, Kenneth Plante, Shannan Rossi, Charalambos D. Partidos, A. Paige Adams, Robert Seymour, James Weger, Erin M. Borland, Michael Sherman, Ann M. Powers, Jorge E. Osorio, Scott Weaver

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Chikungunya virus (CHIKV) is the mosquito-borne alphavirus that is the etiologic agent of massive outbreaks of arthralgic febrile illness that recently affected millions of people in Africa and Asia. The only CHIKV vaccine that has been tested in humans, strain 181/clone 25, is a live-attenuated derivative of Southeast Asian human isolate strain AF15561. The vaccine was immunogenic in phase I and II clinical trials; however, it induced transient arthralgia in 8% of the vaccinees. There are five amino acid differences between the vaccine and its parent, as well as five synonymous mutations, none of which involves cis-acting genome regions known to be responsible for replication or packaging. To identify the determinants of attenuation, we therefore tested the five nonsynonymous mutations by cloning them individually or in different combinations into infectious clones derived from two wild-type (WT) CHIKV strains, La Reunion and AF15561. Levels of virulence were compared with those of the WT strains and the vaccine strain in two different murine models: infant CD1 and adult A129 mice. An attenuated phenotype indistinguishable from that of the 181/clone 25 vaccine strain was obtained by the simultaneous expression of two E2 glycoprotein substitutions, with intermediate levels of attenuation obtained with the single E2 mutations. The other three amino acid mutations, in nsP1, 6K, and E1, did not have a detectable effect on CHIKV virulence. These results indicate that the attenuation of strain 181/clone 25 is mediated by two point mutations, explaining the phenotypic instability observed in human vaccinees and also in our studies.

Original languageEnglish (US)
Pages (from-to)6084-6096
Number of pages13
JournalJournal of Virology
Volume86
Issue number11
DOIs
StatePublished - Jun 2012

Fingerprint

Chikungunya virus
amino acid substitution
Amino Acid Substitution
glycoproteins
Glycoproteins
Vaccines
Clone Cells
clones
vaccines
mutation
Mutation
Virulence
Reunion
Alphavirus
Amino Acids
Phase II Clinical Trials
Clinical Trials, Phase I
virulence
Arthralgia
Product Packaging

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the e2 envelope glycoprotein. / Gorchakov, Rodion; Wang, Eryu; Leal, Grace; Forrester, Naomi L.; Plante, Kenneth; Rossi, Shannan; Partidos, Charalambos D.; Adams, A. Paige; Seymour, Robert; Weger, James; Borland, Erin M.; Sherman, Michael; Powers, Ann M.; Osorio, Jorge E.; Weaver, Scott.

In: Journal of Virology, Vol. 86, No. 11, 06.2012, p. 6084-6096.

Research output: Contribution to journalArticle

Gorchakov, R, Wang, E, Leal, G, Forrester, NL, Plante, K, Rossi, S, Partidos, CD, Adams, AP, Seymour, R, Weger, J, Borland, EM, Sherman, M, Powers, AM, Osorio, JE & Weaver, S 2012, 'Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the e2 envelope glycoprotein', Journal of Virology, vol. 86, no. 11, pp. 6084-6096. https://doi.org/10.1128/JVI.06449-11
Gorchakov, Rodion ; Wang, Eryu ; Leal, Grace ; Forrester, Naomi L. ; Plante, Kenneth ; Rossi, Shannan ; Partidos, Charalambos D. ; Adams, A. Paige ; Seymour, Robert ; Weger, James ; Borland, Erin M. ; Sherman, Michael ; Powers, Ann M. ; Osorio, Jorge E. ; Weaver, Scott. / Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the e2 envelope glycoprotein. In: Journal of Virology. 2012 ; Vol. 86, No. 11. pp. 6084-6096.
@article{0eb7917a8ebe4eec9961b325b0eb97ce,
title = "Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the e2 envelope glycoprotein",
abstract = "Chikungunya virus (CHIKV) is the mosquito-borne alphavirus that is the etiologic agent of massive outbreaks of arthralgic febrile illness that recently affected millions of people in Africa and Asia. The only CHIKV vaccine that has been tested in humans, strain 181/clone 25, is a live-attenuated derivative of Southeast Asian human isolate strain AF15561. The vaccine was immunogenic in phase I and II clinical trials; however, it induced transient arthralgia in 8{\%} of the vaccinees. There are five amino acid differences between the vaccine and its parent, as well as five synonymous mutations, none of which involves cis-acting genome regions known to be responsible for replication or packaging. To identify the determinants of attenuation, we therefore tested the five nonsynonymous mutations by cloning them individually or in different combinations into infectious clones derived from two wild-type (WT) CHIKV strains, La Reunion and AF15561. Levels of virulence were compared with those of the WT strains and the vaccine strain in two different murine models: infant CD1 and adult A129 mice. An attenuated phenotype indistinguishable from that of the 181/clone 25 vaccine strain was obtained by the simultaneous expression of two E2 glycoprotein substitutions, with intermediate levels of attenuation obtained with the single E2 mutations. The other three amino acid mutations, in nsP1, 6K, and E1, did not have a detectable effect on CHIKV virulence. These results indicate that the attenuation of strain 181/clone 25 is mediated by two point mutations, explaining the phenotypic instability observed in human vaccinees and also in our studies.",
author = "Rodion Gorchakov and Eryu Wang and Grace Leal and Forrester, {Naomi L.} and Kenneth Plante and Shannan Rossi and Partidos, {Charalambos D.} and Adams, {A. Paige} and Robert Seymour and James Weger and Borland, {Erin M.} and Michael Sherman and Powers, {Ann M.} and Osorio, {Jorge E.} and Scott Weaver",
year = "2012",
month = "6",
doi = "10.1128/JVI.06449-11",
language = "English (US)",
volume = "86",
pages = "6084--6096",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the e2 envelope glycoprotein

AU - Gorchakov, Rodion

AU - Wang, Eryu

AU - Leal, Grace

AU - Forrester, Naomi L.

AU - Plante, Kenneth

AU - Rossi, Shannan

AU - Partidos, Charalambos D.

AU - Adams, A. Paige

AU - Seymour, Robert

AU - Weger, James

AU - Borland, Erin M.

AU - Sherman, Michael

AU - Powers, Ann M.

AU - Osorio, Jorge E.

AU - Weaver, Scott

PY - 2012/6

Y1 - 2012/6

N2 - Chikungunya virus (CHIKV) is the mosquito-borne alphavirus that is the etiologic agent of massive outbreaks of arthralgic febrile illness that recently affected millions of people in Africa and Asia. The only CHIKV vaccine that has been tested in humans, strain 181/clone 25, is a live-attenuated derivative of Southeast Asian human isolate strain AF15561. The vaccine was immunogenic in phase I and II clinical trials; however, it induced transient arthralgia in 8% of the vaccinees. There are five amino acid differences between the vaccine and its parent, as well as five synonymous mutations, none of which involves cis-acting genome regions known to be responsible for replication or packaging. To identify the determinants of attenuation, we therefore tested the five nonsynonymous mutations by cloning them individually or in different combinations into infectious clones derived from two wild-type (WT) CHIKV strains, La Reunion and AF15561. Levels of virulence were compared with those of the WT strains and the vaccine strain in two different murine models: infant CD1 and adult A129 mice. An attenuated phenotype indistinguishable from that of the 181/clone 25 vaccine strain was obtained by the simultaneous expression of two E2 glycoprotein substitutions, with intermediate levels of attenuation obtained with the single E2 mutations. The other three amino acid mutations, in nsP1, 6K, and E1, did not have a detectable effect on CHIKV virulence. These results indicate that the attenuation of strain 181/clone 25 is mediated by two point mutations, explaining the phenotypic instability observed in human vaccinees and also in our studies.

AB - Chikungunya virus (CHIKV) is the mosquito-borne alphavirus that is the etiologic agent of massive outbreaks of arthralgic febrile illness that recently affected millions of people in Africa and Asia. The only CHIKV vaccine that has been tested in humans, strain 181/clone 25, is a live-attenuated derivative of Southeast Asian human isolate strain AF15561. The vaccine was immunogenic in phase I and II clinical trials; however, it induced transient arthralgia in 8% of the vaccinees. There are five amino acid differences between the vaccine and its parent, as well as five synonymous mutations, none of which involves cis-acting genome regions known to be responsible for replication or packaging. To identify the determinants of attenuation, we therefore tested the five nonsynonymous mutations by cloning them individually or in different combinations into infectious clones derived from two wild-type (WT) CHIKV strains, La Reunion and AF15561. Levels of virulence were compared with those of the WT strains and the vaccine strain in two different murine models: infant CD1 and adult A129 mice. An attenuated phenotype indistinguishable from that of the 181/clone 25 vaccine strain was obtained by the simultaneous expression of two E2 glycoprotein substitutions, with intermediate levels of attenuation obtained with the single E2 mutations. The other three amino acid mutations, in nsP1, 6K, and E1, did not have a detectable effect on CHIKV virulence. These results indicate that the attenuation of strain 181/clone 25 is mediated by two point mutations, explaining the phenotypic instability observed in human vaccinees and also in our studies.

UR - http://www.scopus.com/inward/record.url?scp=84863613754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863613754&partnerID=8YFLogxK

U2 - 10.1128/JVI.06449-11

DO - 10.1128/JVI.06449-11

M3 - Article

VL - 86

SP - 6084

EP - 6096

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 11

ER -